Ginseng protein improves the subacute Parkinson's model

Area of Science:

• Neuroscience
• Pharmacology
• Microbiology

Background:

• Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms and the loss of dopaminergic neurons.
• The gut microbiome has been implicated in the pathogenesis and progression of PD.
• Ginseng protein (GP) is a potential therapeutic agent with antioxidant and anti-inflammatory properties.

Purpose of the Study:

• To investigate the ameliorative effects of total ginseng protein (GP) on Parkinson's disease (PD) in vitro and in vivo.
• To assess the impact of GP on the intestinal flora in a mouse model of PD.

Main Methods:

• In vitro: PC12 cells were exposed to MPP+ to induce cellular damage.
• In vivo: A subacute PD model was established in C57BL/6 mice using MPTP injections.
• Analyses included cell viability assays, behavioral tests, brain histopathology, and gut microbiota profiling.

Main Results:

• GP treatment protected PC12 cells from MPP+-induced apoptosis and improved survival rates.
• In MPTP-induced PD mice, GP administration significantly improved motor function, antioxidant capacity, and restored hippocampal neuron integrity.
• GP treatment upregulated tyrosine hydroxylase (TH) and downregulated α-synuclein (α-Syn) expression in the brain.
• GP modulated gut microbial diversity and shifted community structure towards a healthier profile.

Conclusions:

• Total ginseng protein (GP) demonstrates significant ameliorative effects on cellular damage and neurological deficits associated with Parkinson's disease.
• GP treatment positively influences brain histopathology and restores intestinal flora balance in a mouse model of PD.
• GP holds potential as a therapeutic agent for Parkinson's disease, addressing both central nervous system and gut microbiome aspects.